Performance Scale Examination

1918 ◽  
Author(s):  
Keyword(s):  
2005 ◽  
Author(s):  
James Wiley ◽  
Ian Wilkinson ◽  
Louise Young

Author(s):  
Encarna Rodríguez ◽  
Carolina Chabrera ◽  
Mariona Farrés ◽  
Jordi Castillo ◽  
Montse Virumbrales ◽  
...  

2021 ◽  
pp. 1-5
Author(s):  
Guk Jin Lee ◽  
Ji Hyun Gwak ◽  
Myoung Sim Kim ◽  
Mi Yeong Lee ◽  
Seo Ree Kim ◽  
...  

Abstract Objective The accurate estimation of expected survival in terminal cancer patients is important. The palliative performance scale (PPS) is an important factor in predicting survival of hospice patients. The purpose of this study was to examine how initial status of PPS and changes in PPS affect the survival of hospice patients in Korea. Method We retrospectively examined 315 patients who were admitted to our hospice unit between January 2017 and December 2018. The patients were divided based on the PPS of ≥50% (group A) and ≤40% (group B). We performed survival analysis for factors associated with the length of survival (LOS) in group A. Based on the hospice team's weekly evaluation of PPS, we examined the effect of initial levels and changes in group A on the prognosis of patients who survived for 2 weeks or more. Results At the time of admission to hospice, 265 (84.1%) patients were PPS ≥50%, and 50 (15.9%) were PPS ≤40%. The median LOS of PPS ≥50% and PPS ≤40% were 15 (2–158 days) and 9 (2–43 days), respectively. Male, gastrointestinal cancer, and lower initial PPS all predicted poor prognosis in group A. Male, gastrointestinal cancer, and a PPS change of 10% or greater, compared with initial status 1 week and 2 weeks of hospitalization, were all predictors of poor prognosis in group A patients who survived for 2 weeks or longer. Significance of results Our research demonstrates the significance of PPS change at 1 week and 2 weeks, suggesting the importance of evaluating not only initial PPS but also change in PPS.


2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Yufeng Zhou

Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity focused ultrasound (HIFU) is becoming an emerging approach of noninvasively ablating solid tumor in clinics. A variety of solid tumors have been tried on thousands of patients in the last fifteen years with great success. The principle, mechanism, and clinical outcome of HIFU were introduced first. All 3022 clinical cases of HIFU treatment for the advanced pancreatic cancer alone or in combination with chemotherapy or radiotherapy in 241 published papers were reviewed and summarized for its efficacy, pain relief, clinical benefit rate, survival, Karnofsky performance scale (KPS) score, changes in tumor size, occurrence of echogenicity, serum level, diagnostic assessment of outcome, and associated complications. Immune response induced by HIFU ablation may become an effective way of cancer treatment. Comments for a better outcome and current challenges of HIFU technology are also covered.


1984 ◽  
Vol 54 (3) ◽  
pp. 755-758 ◽  
Author(s):  
Daniel R. Panitz ◽  
Alan Feingold

The internal consistency of the Beta II, a recent revision of the Revised Beta Examination, was examined for a sample of alcoholic inpatients (81 men, 19 women) of low ability and socioeconomic status. They were aged 19 to 65 yr. ( M = 36.6, SD = 9.2) and had been admitted for treatment at a state agency for rehabilitation for alcoholism. Pearson inter-correlations were reported as well as the correlations between subtests and the sums of scaled scores. The median subtest intercorrelation was .51 and the median subtest-sum of scaled scores correlation was .76. Although these coefficients were smaller than those reported for the previous edition of the Beta, they compared favorably with results obtained for the recent revision of the Performance scale of the WAIS.


Sign in / Sign up

Export Citation Format

Share Document